Hepatic: Increase of GOT-AL-P-LDH-total bilirubin level, decrease of serum total protein may occur. Hepatic impairment accompanied by venae hepaticae thrombosis and hepatocyte sphacelism has been reported; if they occur, the administration should be discontinued or appropriate therapy instituted.
Renal: Increase of BUN, proteinuria may occur.
Hypersensitivity: Anaphylaxis, photosensitivity may occur.
Gastrointestinal: Nausea, vomiting, anorexia, diarrhea, and gastralgia may occur.
Nervous System: Giddiness, mouth numbness, facial paresthesia may occur.
Dermatologic: Erythematous eruption, urticaria, alopecia may occur.
Site of Injection: Vascular pain may occur.
Other: Malaise, myalgia, headache, ruber, flush, influenza-like syndrome may occur.
View ADR Reporting Link